Innovation stocks present a double-edged sword for investors, offering both tremendous potential and significant risk. These equities, often associated with cutting-edge technologies or breakthrough scientific discoveries, can indeed skyrocket when research and development efforts yield positive results.
However, the path of innovation is fraught with challenges and uncertainties. Many promising ideas fail to materialize into viable products or services. After all, the process of turning a concept into a marketable offering is complex, time-consuming, and capital-intensive. Regulatory hurdles, technical setbacks, or shifts in market demand can derail even the most promising innovations.
Image source: Getty Images.
Gene-editing pioneer CRISPR Therapeutics (CRSP -2.47%) stands out in this regard. Despite serious doubt from many in the scientific community, the biotech successfully advanced its gene-edited therapy Casgevy through clinical trials and subsequently won regulatory approvals in several territories such as the U.S., U.K., the European Union, and the Kingdom of Saudi Arabia for both sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
CRISPR is partnering with biotech heavyweight Vertex Pharmaceuticals (VRTX -0.80%), and Wall Street thinks Casgevy will eventually top $1 billion in annual sales, perhaps by the end of the decade. Even so, CRISPR Therapeutics stock has barely budged in the past 12 months:
Is this quiet period a buying opportunity? One analyst definitely thinks so.
CRISPR Therapeutics might be severely undervalued
Morningstar analyst Rachel Elfman recently placed a $119 fair-value estimate on CRISPR Therapeutics' shares. At current levels, this estimate implies a whopping upside potential of 114%.
What's driving this sky-high fair-value estimate? While commercialization concerns have some analysts rattled due to Casgevy's burdensome logistics, Vertex Pharmaceuticals is shepherding the drug's commercial launch.
While it's indeed true that Casgevy is unlikely to post mind-blowing numbers, the chances of the therapy becoming a strong revenue generator within the next two to three years are favorable. The problem is Wall Street's short attention span. Traders rarely think long term, and CRISPR Therapeutics stock is undeniably a long-term investment.
After all, the company's other pipeline candidates in oncology, autoimmune, diabetes, and cardiovascular care are in early-stage development. Casgevy's commercial launch will also require a year or longer to ramp up. In short, CRISPR Therapeutics stock requires patience.
Verdict
By all accounts, Casgevy represents a major leap forward in the treatment of SCD and TDT. As such, the drug stands an excellent chance of becoming widely adopted by prescribers in the space.
However, the revolutionary nature of Casgevy is matched by the complexity of its administration. Unlike traditional medications, this gene therapy involves a multistep process that requires specialized facilities and expertise.
This fact means that investors shouldn't expect a significant penetration rate during Casgevy's first few quarters on the market. Consequently, Elfman's lofty fair-value estimate might be a tad premature.
But time is on the side of shareholders in this case. Casgevy is highly unlikely to be a commercial flop. If you're willing to hold this biotech stock for a minimum of five years, you should benefit significantly from the market's short-sightedness.
